To evaluate PU.1 as a potential therapeutic target for anti-cancer immunotherapy by reprogramming TAMs, we have investigated the effects and mechanisms of action of the PU.1 inhibitor DB in a mouse melanoma model. The gene discussed is SPI1; the disease is melanoma.